- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma
April 12th 2022, 8:59pm
The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.
BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma
April 12th 2022, 8:30pm
The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.
Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors
April 12th 2022, 7:56pm
Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.
MEDI5752 Demonstrates Intriguing Activity in Advanced Solid Tumors
April 12th 2022, 7:55pm
MEDI5752 treatment led to a dose-dependent increase in peripheral T-cell proliferation and encouraging antitumor activity in patients with advanced solid tumors.
Addition of NG-641 to Nivolumab Under Exploration in Epithelial Tumors
April 12th 2022, 7:06pm
The combination of the novel adenoviral vector NG-641 and nivolumab is being investigated in patients in the phase 1a/b NEBULA trial in patients with previously treated metastatic or advanced epithelial tumors.
Resistance to CAR T-Cell Therapy Predicted by Epigenetic Biomarkers in Pediatric ALL
April 12th 2022, 6:27pm
Resistance to CD19-directed CAR T-cell therapy was associated with molecular characteristics identified in pediatric patients with acute lymphoblastic leukemia.
Dr. Tagawa on the Investigation of 225Ac-J591 and 177Lu-PSMA-I&T in mCRPC
April 12th 2022, 12:24pm
Scott T. Tagawa, MD, MS, FACP, discusses the investigation of 225Ac-J591 and 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer in a phase 1/2 trial.
ZN-c3 Shows Preliminary Efficacy, Safety in Recurrent/Advanced Uterine Serous Carcinoma
April 12th 2022, 12:40am
The investigational Wee1 inhibitor ZN-c3 was found to be safe and to produce a disease control rate of 90.9% and an objective response rate of 27.3% in patients with advanced or recurrent uterine serous carcinoma.
Fixed-Duration Ibrutinib Plus Venetoclax Demonstrates Efficacy in High-Risk CLL and SLL
April 12th 2022, 12:30am
The combination of ibrutinib and venetoclax administered for a fixed duration elicited durable responses and sustained progression-free survival in previously untreated, high-risk patients with chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from the phase 2 CAPTIVATE trial.
gLOH-High Status Is Associated With Enhanced Response to Talazoparib in mCRPC
April 11th 2022, 11:56pm
High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.
JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors
April 11th 2022, 11:18pm
The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.
Combined Immune Pathway Inhibition Improves Responses in Resectable NSCLC
April 11th 2022, 9:25pm
Durvalumab plus either oleclumab, monalizumab, or damvatirsen led to an improvement in major pathologic response vs durvalumab alone as neoadjuvant therapy in patients with resectable, early-stage non–small cell lung cancer, according to findings from the phase 2 NeoCOAST clinical trial.
Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC
April 11th 2022, 8:45pm
The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.
Pembrolizumab Plus Chemotherapy Elicits Meaningful pCR for Gastric, GEJ Adenocarcinoma
April 11th 2022, 8:15pm
Perioperative pembrolizumab plus standard of care chemotherapy followed by adjuvant pembrolizumab showed a meaningful pathological complete response rate in patients with resectable gastric and gastroesophageal junction adenocarcinoma.
YAP1, Inflamed T-Cell Subtypes Linked With Improved Durvalumab/ Chemo Responses in ES-SCLC
April 11th 2022, 5:25pm
Patients with extensive-stage small cell lung cancer whose disease harbors inflamed or YAP1 molecular subtypes may be more likely to derive superior overall survival benefit from durvalumab and chemotherapy vs those with other overexpressed biomarkers.
Nivolumab/Chemotherapy Generate Survival Benefit Vs Chemotherapy Alone in Gastric Cancer, Regardless of TMB
April 11th 2022, 3:41pm
The combination of nivolumab with chemotherapy elicited a higher overall survival rate compared with chemotherapy alone in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, regardless of tumor mutational burden (TMB) status.
Nivolumab/Ipilimumab Produces Promising ORR in Advanced tTMB- and bTMB-High Solid Tumors
April 11th 2022, 1:05am
The dual immunotherapy combination of nivolumab and ipilimumab elicited encouraging and durable responses with acceptable safety in patients with advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies, meeting the primary end points of the phase 2 CheckMate-848 trial.
Elimusertib Elicits Responses in Solid Tumors With ATM Alterations and BRCA Mutations
April 11th 2022, 12:40am
The oral ataxia-telangiectasia and Rad3–related protein inhibitor elimusertib produced durable and prolonged responses in patients with advanced solid tumors who have ATM gene alterations and BRCA1/2 defects.
Olaparib Combination Shows Notable Non-Progression Rate in Endometrial Cancer
April 11th 2022, 12:01am
In the ENDOLA trial, olaparib in combination with metronomic cyclophosphamide and metformin showed a significant non-progression rate in patients with recurrent advanced or metastatic endometrial cancer.
T-Cell Attributes of Axi-cel Linked to Outcomes in LBCL
April 10th 2022, 11:49pm
The T-cell attributes of axicabtagene ciloleucel impacted tumor burden, efficacy outcomes, peak levels of proinflammatory cytokines, and toxicities such as neurologic events and cytokine release syndrome in patients with relapsed/refractory large B-cell lymphoma.